Intelligent Bio Solutions Inc. (INBS)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 2 | 0 | 1 | 3 | 3 | 4 | 4 |
| Operating profit | $m | -11 | -13 | ||||||
| Net profit | $m | -3 | -7 | -8 | -11 | -10 | -11 | -12 | -5 |
| EPS reported | $ | -20.00 | -9.46 | ||||||
| Operating cashflow per share | $ | -18.35 | -6.96 | ||||||
| Capex per share | $ | 0.44 | 0.21 | ||||||
| FCF per share | $ | -18.79 | -7.17 | ||||||
| Free cash flow | $m | -10 | -12 | ||||||
| Net debt | $m | -1 | -4 | ||||||
| Book value equity | $m | 3 | 6 | ||||||
| Book value per share | $ | 5.68 | 1.90 | ||||||
| Number of shares | m | 0.53 | 2.91 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 3.03 | 1.65 | ||||||
| P/S LTM | x | 2.97 | 2.15 | ||||||
| P/FCF LTM | x | -0.92 | -0.74 | ||||||
| EV/EBITDA LTM | x | -0.88 | -0.72 | ||||||
| EV/Sales LTM | x | 2.73 | -0.82 | ||||||
| Earnings Yield LTM | % | -1.17% | -2.63% | ||||||
| FCF Yield | % | -109.24% | -134.55% | ||||||
| Quality | |||||||||
| ROE | % | -352.75% | -174.16% | ||||||
| ROIC | % | -3.35% | -1.10% | ||||||
| Operating margin | % | -3.49% | -3.00% | ||||||
| Gross margin | % | +40.85% | +32.08% | ||||||
| FCF/Sales | % | -324.62% | -292.35% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -1.90% | +35.46% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -35.16 | -6.71 | ||||||
| Net Debt/EBITDA | x | 0.08 | 0.48 | ||||||
| EBIT/Net interest | x | -174.82 | -157.90 | ||||||
| Net debt/market cap | % | +2.17% | +81.60% | ||||||
| Net debt/Equity | x | -0.27 | -0.72 | ||||||
| Gross debt/equity | x | 0.09 | 0.33 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Intelligent Bio Solutions Inc. operates as a life sciences firm focused on developing non-invasive, real-time monitoring and diagnostic solutions for both patients and their primary healthcare providers. A notable product in its portfolio is the Saliva Glucose Biosensor, an organic thin-film transistor designed to precisely measure glucose levels in saliva for effective diabetes management. Beyond this, the company is actively developing a SARS-CoV-2 Biosensor, intended to serve as a supplementary diagnostic tool to existing RNA virus detection methods. It also maintains a broad biosensor platform that encompasses diverse diagnostic modalities, including biochemistry, immunology, tumor marker identification, hormone analysis, and nucleic acid diagnostics. Incorporated in 2016 and based in New York, New York, the company was formerly known as GBS Inc. before adopting its current name in October 2022. Intelligent Bio Solutions Inc. operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Intelligent Bio Solutions Inc. (INBS)
No price history available.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Intelligent Bio Solutions Inc. operates as a life sciences firm focused on developing non-invasive, real-time monitoring and diagnostic solutions for both patients and their primary healthcare providers. A notable product in its portfolio is the Saliva Glucose Biosensor, an organic thin-film transistor designed to precisely measure glucose levels in saliva for effective diabetes management. Beyond this, the company is actively developing a SARS-CoV-2 Biosensor, intended to serve as a supplementary diagnostic tool to existing RNA virus detection methods. It also maintains a broad biosensor platform that encompasses diverse diagnostic modalities, including biochemistry, immunology, tumor marker identification, hormone analysis, and nucleic acid diagnostics. Incorporated in 2016 and based in New York, New York, the company was formerly known as GBS Inc. before adopting its current name in October 2022. Intelligent Bio Solutions Inc. operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free